Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.72 |
| ▸ | PI4KA | P42356 | 2/20 | 0.72 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.72 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.72 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.72 |
| ▸ | DPP4 | P27487 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.72 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.72 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.72 |
| ▸ | GAPDH | P04406 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.72 |
| ▸ | STAT6 | P42226 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20493425 | 1.00 | ADORA3 (0.72) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL30670297 | 1.00 | ADORA3 (0.72) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1019966 | 1.00 | ADORA3 (0.72) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12031327 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25936 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24538798 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25937 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2550330 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23050294 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12150808 | 0.91 | ADORA3 (0.75) | ADORA3ADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683645-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE SILENCING | Atalanta Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| WO-2024197280-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE SILENCING | ATALANTA THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| EP-4159741-A1 | METHOD FOR PRODUCING A CHIMERIC POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING A TRIAZOLE-CONTAINING INTERNUCLEOTIDE LINKAGE | ModernaTX, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| EP-3169693-B1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3169335-B1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | claimed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | claimed |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-20 | — | — | US | claimed |
| EP-3169693-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | claimed |
| EP-3169335-A2 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | claimed |
| WO-2016011222-A2 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | claimed |
| WO-2016011226-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | claimed |
| EP-4683645-A1 | COMPOSITIONS AND METHODS FOR IMPROVED GENE SILENCING | Atalanta Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4374873-B1 | AGENT FOR USE IN TREATING OR PREVENTING OPTHALMOLOGICAL CONDITIONS | ASTELLAS US LLC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3350333-B2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNATX INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250186624-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ARES CAPITAL CORPORATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| WO-2008000744-A2 | 2-0'-METHYLADEN0SINE DERIVATIVES AND THEIR USE AS AGONISTS OR ANTAGONISTS OF AN ADENOSINE RECEPTOR | BIOVITRUM AB (PUBL) (SE) | 2008-01-03 | — | — | WO | disclosed |
| CN-100355769-C | 2'-methoxy adenosine preparation method | UNIV EAST CHINA NORMAL (CN) | 2007-12-19 | — | — | CN | disclosed |
| CN-100355769-C | 2'-methoxy adenosine preparation method | UNIV EAST CHINA NORMAL (CN) | 2007-12-19 | — | — | CN | disclosed |
| WO-2007120657-A2 | CRYSTALS OF A BACTERIAL METABOLITE-SENSING RIBOZYME AND USE THEREOF FOR ANTIBIOTIC DISCOVERY | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2007-10-25 | — | — | WO | disclosed |
| CN-1765913-A | 2'-methoxy adenosine preparation method | UNIV EAST CHINA NORMAL (CN) | 2006-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | ADORA3 1887/4885ADORA1 2692/4885PI4KA 1709/4885 |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | POLN, POLRMT, POLI | ADORA3 2287/4885ADORA1 3511/4885PI4KA 2066/4885 |
| US-20250186624-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | POLR2E, POLN, PHAX | ADORA3 4047/4885ADORA1 4705/4885PI4KA 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.